A carregar...
A phase II trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
BACKGROUND: Abiraterone acetate suppresses adrenal androgens and glucocorticoids by inhibition of CYP17; however, given the risk of mineralocorticoid excess, it is administered with glucocorticoids. We performed a phase 2, single-arm study, designed to assess the safety of abiraterone acetate withou...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6353689/ https://ncbi.nlm.nih.gov/pubmed/30427533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31836 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|